Drugs / TMB-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05295732 | Jun 2022 → Jun 2024 | ichthyosis | LEO Pharma | Completed | Missed primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-08-21 | LEO Pharma | Timber Pharmaceuticals, Inc., a LEO Pharma Company, provides an update on the development program for TMB-001 in congenital ichthyosis leo-pharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TMB-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05295732 ↗ |
| Route | Topical | “Topical TMB-001 0.05% QD/BID” NCT05295732 ↗ |